<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516659</url>
  </required_header>
  <id_info>
    <org_study_id>ELT206</org_study_id>
    <nct_id>NCT00516659</nct_id>
  </id_info>
  <brief_title>ETEC Logistics Trial (TREK)</brief_title>
  <acronym>Trek</acronym>
  <official_title>A Phase II, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection With Enterotoxigenic Escherichia Coli Occurring After Transcutaneous Immunization in a Field Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercell USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercell USA, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, randomized, placebo-controlled field trial to evaluate
      the epidemiology of natural infection with ETEC occurring after transcutaneous immunization
      in a field setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of the study are to evaluate the incidence of ETEC illness in a field
      setting and to compare the safety of LT delivered by TCI with placebo. The secondary
      objectives include, but are not limited to:

      evaluate the stool frequency per episode of ETEC illness in placebo recipients, to evaluate
      the immunogenicity of LT delivered by TCI, to evaluate the incidence of IBS following travel
      to areas of ETEC endemnicity, and to evaluate the incidence of VPO in placebo and LT patch
      recipients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Enterotoxigenic Escherichia coli (ETEC) illness defined as a diarrheal episode associated with an LT, LT/ST, or ST-positive ETEC strain isolated from a sample of a stool</measure>
    <time_frame>during the diarrheal episode or within 48 hours after the last stool in the diarrheal episode.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of heat-labile enterotoxin of Escherichia coli (LT) delivered by transcutaneous immunization (TCI) vs placebo</measure>
    <time_frame>From vaccination 1 to completion of Day 180 follow-up, about a seven month time period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool frequency per episode of ETEC illness in placebo recipients</measure>
    <time_frame>Duration of stay in Mexico or Guatemala assessed up to four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of LT delivered by TCI</measure>
    <time_frame>at least three weeks prior to arrival in country, arrival in Mexico or Guatemala, and 5 to 18 days after arrival</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of irritable bowel syndrome following travel to areas of ETEC endemnicity.</measure>
    <time_frame>Baseline through six months post return from Latin America. A period of about six months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of vaccine preventable outcome in placebo and LT patch recipients.</measure>
    <time_frame>Duration of each individual participant stay in Mexico or Guatemala ranging from 7 to 28 Days.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Heat-Labile Enterotoxin of Escherichia coli (LT)</intervention_name>
    <description>Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult men and women 18-64 years of age inclusive at screening

          -  Signed Informed Consent form

          -  Planned travel to an area within 2 ½ hours traveling distance of Cuernavaca or
             Guadalajara, Mexico or Antigua, Guatemala (minimum stay of 7 days)

          -  If female who is not post-menopausal or surgically sterile, negative pregnancy test
             (within 24 hours prior to vaccination) and agreement to employ an effective form of
             birth control or practice abstinence through the end of the study.

        Exclusion Criteria:

          -  Clinically significant abnormalities as determined by the Investigator/clinician
             during physical inspection

          -  Received investigational product from 30 days before date of first vaccination or
             during the entire study period

          -  Ever received LT, ETEC, or cholera vaccine

          -  History of traveler's diarrhea within the previous year

          -  Travel to a developing country within the last year

          -  Women who are pregnant or breastfeeding

          -  History of achlorhydria

          -  Evidence of immunosuppression, including concomitant immunosuppressive therapy; fever
             &gt; 99.5°F (37.5°C) on day of vaccination

          -  Current problems with alcohol or substance abuse

          -  An employee of the study clinic

          -  Sensitivity or allergy to any of the vaccine components

          -  History of significant blood loss, blood product donation, or blood product recipient
             in the previous 60 days

          -  Planned use of Imodium or antibiotics for self treatment of diarrhea during the study
             period

          -  Visible tattoos or marks (tattoos/scars) at the vaccination areas that would prevent
             appropriate dermatologic monitoring of the vaccination sites; and

          -  Medical history of acute or chronic GI illness or major GI surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert L. DuPont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Infectious Diseases, The University of Texas Health Science Center at Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robin McKenzie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University, Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rama Yerramsetti</last_name>
    <role>Principal Investigator</role>
    <affiliation>Breco Research, Houston, TX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William P Jennings</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research, San Antonio, TX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yu-Luen Hsu</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Coast Clinical Trials, Long Beach, CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher A Smith</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asthma &amp; Allergy Associates, Ithaca, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benno G Roesch</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Biomedical Research, Hackensack, NJ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey G Geohas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research, Chicago, IL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilbert Podolsky</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jean Brown Research, Salt Lake City, UT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Lagen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwest Kinetics, Tacoma, WA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roy M Fleischmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research, Dallas, TX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Douglas R Schumacher</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research, Columbus, OH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norman M Lunde</last_name>
    <role>Principal Investigator</role>
    <affiliation>Twin Cities Clinical Research, Minneapolis, MN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco G Sandoval</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Autonoma De Guadalajara, Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Hector M Romero</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Autonoma Guadalajara, Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaime B Gerson</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas, Cuernavaca, Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edwin Asturias</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad del Valle de Guatemala (Antigua)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Garcia</last_name>
    <role>Principal Investigator</role>
    <affiliation>AmeriMed Puerto Vallarta, Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martha V Serrato</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Americano, Cancun, Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Maxwell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Clinic, San Miguel de Allende, Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University, Bloomberg School of Public Health</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twin Cities Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Biomedical Research</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma Allergy &amp; Associates</name>
      <address>
        <city>Ithica</city>
        <state>New York</state>
        <zip>14850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breco Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Infectious Diseases, The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Kinetics</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic Antigua</name>
      <address>
        <city>Antigua Guatemala</city>
        <zip>03001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic San Miguel</name>
      <address>
        <city>San Miguel de Allende</city>
        <state>Guanajuata</state>
        <zip>37700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AmeriMed Hospital</name>
      <address>
        <city>Puerto Vallarta</city>
        <state>Marina Vallarta</state>
        <zip>48334</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic Cuernavaca</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62250</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Americano</name>
      <address>
        <city>Cancun</city>
        <state>Quintana Roo</state>
        <zip>77500</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guatemala</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.trekstudy.com</url>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2007</study_first_submitted>
  <study_first_submitted_qc>August 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2007</study_first_posted>
  <last_update_submitted>March 13, 2012</last_update_submitted>
  <last_update_submitted_qc>March 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ETEC</keyword>
  <keyword>Traveler's diarrhea</keyword>
  <keyword>TCI</keyword>
  <keyword>patch vaccine</keyword>
  <keyword>diarrhea prevention</keyword>
  <keyword>epidemiology ETEC</keyword>
  <keyword>Escherichia coli</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

